Search Results
Your search for ,are matches 21906 pages
Showing 6151 - 6200Adjuvant Imatinib Therapy Offers Survival Benefit in Patients With Resected GIST, but Team Effort May Be Needed to Reduce Early Discontinuation Rates
Clinical trial data show that adjuvant imatinib improves recurrence-free survival as well as overall survival, when administered for at least 3 years, among patients who undergo a macroscopically complete resection of a primary gastrointestinal stromal tumor (GIST), Chandrajit P. Raut, MD, MSc,...
Fox Chase Cancer Center’s Jennifer Barsky Reese, PhD, Receives New Investigator Award
Jennifer Barsky Reese, PhD, Associate Professor for the Cancer Prevention and Control Program at Fox Chase Cancer Center, was recently recognized with the New Investigator Award from the American Psychosocial Oncology Society (APOS). “I am extremely honored to get this award. This is a testament...
‘Radiation Is Not the Enemy’
“I want to make very clear that radiation is not the enemy,” Monika Metzger, MD, MSc, emphasized in discussing a study she led on the integration of brentuximab vedotin into the front-line treatment of pediatric patients with high-risk Hodgkin lymphoma. The study yielded excellent results while...
Adding Targeted Agent to Treatment Shows Significant Benefits in Pediatric Patients With High-Risk Hodgkin Lymphoma
Integrating the antibody-drug conjugate brentuximab vedotin into the front-line treatment of pediatric patients with high-risk Hodgkin lymphoma “facilitated significant reduction in radiation exposure and yielded excellent outcomes,” Monika Metzger, MD, MSc, Director for the Central and South...
Disease-Free Survival Benefit With Adjuvant Immunotherapy in Resectable Esophageal Cancer: Practice-Changing for All Patients?
The CheckMate 577 trial—reported in The New England Journal of Medicine by Kelly et al1 and reviewed in this issue of The ASCO Post—is the first global randomized controlled trial for patients with resectable esophageal cancer that showed a significant disease-free survival benefit for adjuvant...
Cabozantinib With Nivolumab for Metastatic Renal Cell Carcinoma: A New Front-Line Standard
The pace of clinical research in metastatic renal cell carcinoma is faster than ever. Over the past 5 years, we have seen data from six phase III clinical trials evaluating combination strategies with checkpoint inhibitors. The era began with data from CheckMate 214, evaluating nivolumab with...
Atezolizumab Reduces Risk of Disease Progression in Patients With PD-L1–Expressing Early-Stage NSCLC
Atezolizumab given after chemotherapy to patients with resected stage II to IIIA non–small cell lung cancer (NSCLC) significantly improved disease-free survival compared with best supportive care alone in patients whose tumors expressed PD-L1.1 These results of the global phase III IMpower010 trial ...
How the Biden Administration Is Changing Oncology Care
A change in presidential administrations has implications across the health sector, including for oncology. In this column, we review some recent actions by Congress and the Biden administration and their implications for the oncology community. We focus on three areas: funding for patients and...
First Lady Dr. Jill Biden Assures the NCI of the Administration’s Commitment to Advancing Cancer Research
In a virtual visit to the National Cancer Institute (NCI) on February 3, 2021, just 2 weeks after her husband, Joe Biden, was sworn in as the 46th President of the United States, First Lady Jill Biden, EdD, recounted that, in her many years of travel across the United States, she learned that...
Update on Clinical Trials in Acute Myeloid Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on acute myeloid leukemia (AML), such as the use of venetoclax added to...
Study Finds Need to Improve Knowledge About Palliative Care Among U.S. Adults
The use of palliative care in hospitals in the United States has steadily risen over the past decade, with almost universal access to services in large hospitals and academic medical centers. Despite this increased access and recommendations from ASCO that all patients with advanced cancer receive...
Inclusion of Patients With Brain Metastases in Phase III Trials in Advanced Breast Cancer, Lung Cancer, and Melanoma
In a study reported in a research letter in JAMA Oncology, Corbett et al found that the majority of phase III trials investigating systemic therapy in patients with advanced lung cancer, breast cancer, and melanoma over the past 20 years have excluded or restricted enrollment of those with brain...
New Web-Based Lesion Selection Tool May Improve Coordination, Performance, and Management of Biopsy Specimens
In a single-institution study reported in the Journal of Immunotherapy and Precision Oncology, Xu et al found that the use of a Web-based lesion selection tool (LST) developed by the research team improved consistency in lesion selection for sequential biopsy. In addition, the tool improved the...
Expert Point of View: Christine Lovly, MD, PhD
Invited discussant Christine Lovly, MD, PhD, Associate Professor of Medicine, Ingram Associate Professor of Cancer Research, Vanderbilt University Ingram Cancer Center, Nashville, discussed progress in targeted therapies for NSCLC. “We have a tremendous amount of knowledge about driver mutations in ...
More Widespread Biomarker Testing for NSCLC in Oncology Practices and More Testing in Black Patients: An Urgent Priority
Even though next-generation sequencing is recommended by the National Comprehensive Cancer Network (NCCN) for biomarker testing for patients with non–small cell lung cancer (NSCLC), the uptake among community oncology practices is suboptimal, and the uptake is even lower among Black patients with...
Lay Health Worker–Led Intervention May Improve Care for Low-Income and Minority Patients With Cancer
In a study reported in JCO Oncology Practice, Manali I. Patel, MD, MPH, and colleagues found that a lay health worker–led intervention was associated with improved documentation of goals of care, increased clinical trial participation, and increased use of palliative care in a population of...
Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma
In a presentation of real-world data given during the 2021 ASCO Annual Meeting, Miron et al concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to...
Does Vitamin D Supplementation Improve Prognosis for Patients With Breast Cancer?
A research team has found that sufficient vitamin D levels at the time of diagnosis may be associated with improved outcomes among people with breast cancer. These findings were presented by Yao et al during the 2021 ASCO Annual Meeting (Abstract 10510). These findings are based on Kaiser...
ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer
The first overall survival analysis of the WSG-ADAPT HR-/HER2+ study, which evaluated neoadjuvant therapy in patients with hormone receptor (HR)-negative, HER2-positive breast cancer, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or the chemotherapy-free regimen of...
Omid Hamid, MD, Discusses RELATIVITY-047
Omid Hamid, MD, Chief of Translational Research/Immuno-Oncology at The Angeles Clinic & Research Institute, Los Angeles, and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Institute, shared his thoughts on the RELATIVITY-047 study1 for The ASCO Post, referring to them as ...
Targeting LAG-3 and PD-1 With Relatlimab and Nivolumab: A New Option Under Study in Advanced Melanoma
Immune checkpoint inhibition has been established as an effective treatment for patients with metastatic melanoma. A novel immunotherapeutic combination—this one targeting the LAG-3 (lymphocyte-activation gene 3) and PD-1 immune checkpoints—delayed time to disease progression significantly more...
Use of Integrative Medicine by Patients With Breast Cancer
Nearly three-quarters of patients with breast cancer (73%) reported using at least one type of complementary medicine after cancer diagnosis, while surveyed oncologists believed that less than half (43%) of patients were using these approaches during cancer care. These and other findings from a...
No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes
A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...
Results of a Restrictive Opioid Prescription Protocol for Patients With Cancer Undergoing Surgery
Seeing an opportunity to safely reduce the number of opioid doses prescribed to patients with cancer, researchers proposed a new pain management guideline for all patients undergoing surgery at Roswell Park Comprehensive Cancer Center. The results from the first 6 months of that effort, reported by ...
High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma
Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, were presented by Grossmann et al...
Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Immunotherapy following surgery significantly improved disease-free survival compared to placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to results from the international phase III KEYNOTE-564 study presented at the 2021 ASCO Annual Meeting by Toni K....
Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer
The first results from the phase III CheckMate 648 study represent significant progress in the treatment of patients with advanced esophageal squamous cell carcinoma. The trial evaluated first-line treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab in patients with advanced...
Efficacy of Platinum Chemotherapy vs Capecitabine for Basal-Like Triple-Negative Breast Cancer
About 80% of triple-negative breast cancers are classified as the subtype basal-like. Typically, patients with triple-negative breast cancer receive chemotherapy before surgery. The presence of residual cancer in the breast after chemotherapy signals a higher likelihood that the cancer will...
Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...
OUTBACK Trial: No Survival Benefit With Adjuvant Chemotherapy After Standard Chemoradiation for Locally Advanced Cervical Cancer
Cervical cancer is the fourth most common cancer in women worldwide, and the leading cause of cancer-related death among women in Eastern, Western, Middle, and Southern Africa. Globally, in 2018, approximately 570,000 women were diagnosed with cervical cancer, and 311,000 women died. In the United...
Electronic Olfaction System Under Study as Screening Tool for Pancreatic and Ovarian Cancers
An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 ASCO Annual Meeting (Abstract 5544). The findings suggest...
Sotorasib for KRAS G12C–Mutated NSCLC: Overall Survival and Exploratory Subgroup Analyses
Results from the phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and a median overall survival of 12.5 months in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC)....
Transoral Surgery Followed by Lower-Dose Radiation in Patients With HPV-Associated Oropharyngeal Cancer at Intermediate Risk of Recurrence
The phase II E3311 trial offers new information about using reduced-intensity treatment in patients with human papillomavirus (HPV)-associated oropharyngeal cancer who are at intermediate risk of recurrence. These findings were presented by Robert L. Ferris, MD, PhD, and colleagues during the 2021...
OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer
One year of adjuvant therapy with the PARP inhibitor olaparib extended disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer with BRCA1/2 germline mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented by Andrew Tutt, MB ...
Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL
The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...
Community-Based Engagement Initiative Improves Accrual of Black Participants in Clinical Trials
A 5-year community outreach and engagement effort by the Abramson Cancer Center at the University of Pennsylvania to increase enrollment of Black patients into cancer clinical trials more than doubled the percentage of participants, improving access and treatment for a group of patients with...
Study Examines Aromatase Inhibitor–Associated Musculoskeletal Symptoms in a Diverse Population With Early Breast Cancer
A clinical trial in a racially diverse group of postmenopausal women with early breast cancer to study severe pain in the bones, muscles, ligaments, tendons, and nerves caused by aromatase inhibitor treatment has found that the symptoms were more commonly reported in Black and Asian patients than...
Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors
Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with KRAS mutations....
The Daughter of a Fighter Pilot Becomes a Leader in Compassionate Cancer Care
Jamie H. Von Roenn, MD, FASCO, grew up in the suburbs of Chicago as the middle child of three girls. She was, by her own account, extremely shy by nature. Her mother was a graduate of the University of Chicago, but her father’s college education was preempted by his service as a fighter pilot in...
Working on the Night Shift, a Connection to a Patient With Cancer Inspires a Career
Jaap Verweij, MD, PhD, FASCO, was born in 1953 in Velsen, a municipality situated on both sides of the massive North Sea Canal in the Netherlands. His father was a sea captain, and other close family members also plied the oceans for a living in the fishing or transport industries. Dr. Verweij...
A Junior High School Teacher Sparks a Love for Science
Peter Marks, MD, PhD, Director of the U.S. Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER), was born in Brooklyn, New York, near Sheepshead Bay—an area named for the Sheepshead, a fish that can no longer be found in the waters that frame the neighborhood....
After a Flirtation With Infectious Disease, Hematology Calls, Leading to a Notable Career
High-quality cancer care is a complex mixture of science and art, made even more challenging by the dizzying array of coding, billing, and data collection regulations that must be taken into account. Synthesizing all the parts into value-based, whole-patient care across the wide spectrum of the...
A Pioneer in Head and Neck Cancer Surgery Whose Career Was Founded on Passion and Dedication
The term “head and neck surgery” had little meaning until the 1940s, when it was used by groundbreaking surgeon Hayes Martin, MD, in one of his publications. Dr. Martin was then Chief of Head and Neck Services at Memorial Hospital, later renamed Memorial Sloan Kettering Cancer Center (MSK), where...
A Career in Cardio-oncology Founded on Simple Principles Taught by Her Immigrant Parents
Cardio-oncology focuses on the detection, monitoring, and treatment of cardiovascular disease occurring secondary to cancer treatment, and the mechanistic and epidemiologic intersection between cardiovascular disease and cancer. With the advent of targeted agents and immunotherapies,...
Serendipity Plays a Role in a Journey to a Noted Career in Surgical Oncology
Over the past 2 decades, the oncologic mantra “early detection leads to cure” has taken on special meaning in lung cancer, persistently a leading cause of cancer death in the United States. “Over a 25-year period, we’ve seen a revolution in early detection, understanding of tumor biology, and...
A Pioneer in Geriatric Oncology Leaves His Mark and Marches Forward
The field of geriatric oncology has developed steadily over the past several decades, thanks to the dedication of a close-knit community of oncologists who have devoted their careers to advancing multidisciplinary care for older patients with cancer. One such leader is Silvio Monfardini, MD, past...
A Brooklyn Girl Bucks Her Old-Fashioned Upbringing to Become a Leader in Bone Marrow Transplantation
In the face of old school mores, self-motivation and perseverance were needed to build a career as a nationally regarded blood and bone marrow transplant expert. “I was born and reared in Brooklyn, New York, the oldest of seven children of Irish-Italian parents who did not espouse professional...
A Junior High School Teacher Sparks a Love for Science
Peter Marks, MD, PhD, Director of the U.S. Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER), was born in Brooklyn, New York, near Sheepshead Bay—an area named for the Sheepshead, a fish that can no longer be found in the waters that frame the neighborhood....
A Doctor’s Daughter Becomes a Pioneer in Cancer Survivorship
Although quality of life has been an implicit medical outcome since the time of Hippocrates, integrating the explicit effort to assess the effects of cancer treatment on the patient’s quality—and not quantity—of life was spearheaded by dedicated pioneers. One such trailblazer is Patricia A. Ganz,...
New FDA-Approved Oncology Drugs and Label Updates Between May 8, 2020, and May 8, 2021
Over the past year (May 2020–May 2021), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers and adverse events. The new approvals and accelerated approvals are listed below. PEMBROLIZUMAB (KEYTRUDA) in...
